Advances in Viral Hepatitis B and D: Moving Toward the Goals of Elimination., An Issue of Clinics in Liver Disease, 1st Edition
Key Features
-
Contains 13 relevant, practice-oriented topics including Novel Assays to Solve the Clinical and Scientific Challenges of Chronic Hepatitis B; Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus; Triple Threat: HDV, HBV, HIV Coinfection; Targeting Hepatitis B Virus DNA Using Designer Gene Editors; and more.
-
Provides in-depth clinical reviews on Hepatitis B and D, offering actionable insights for clinical practice.
-
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Author Information
| ISBN Number | 9780323939478 |
|---|---|
| Description Author List | Edited by Robert G. Gish, MD, Professor Medicine at Loma Linda University, Adjunct Professor of Medicine at the University of Nevada , School of Medicine in Las Vegas, Clinical Professor at the University of Nevada Reno School of Medicine, Clinical Professor at the University of California Skaggs School of Pharmacy and Pharmaceutical Sciences |
| Copyright Year | 2023 |
| Edition Number | 1 |
| Format | Book |
| Trim | 152w x 229h (6.00" x 9.00") |
| Imprint | Elsevier |
| Page Count | 240 |
| Publication Date | 4 Oct 2023 |
| Stock Status | Please allow 10-14 working days for delivery |


eBooks : Built for busy schedules & tailored for your goals.


Affordable knowledge, built for you
Get the resources you need-often at a lower cost than print. Quality content designed to support your goals, without stretching your budget.


Seamless access wherever you are


Always in sync


Tools the make learning stick
Your eBook is ready whenever you are!
1. Check your email for your access code.


2. Sign into or create your VitalSource account and redeem your code.


3. Open your eBook - ready whenever you are!
FAQ
The access code for your new eBook will be sent in your order confirmation email. Your code can also be accessed in your My Account section on the Elsevier webshop. If you do not receive your code within a few minutes, please check your spam folder.
Step-by-step guidance on how to download Bookshelf and also redeem your code can be found here.
The access code for your new eBook does not expire. However, we always suggest redeeming immediately after purchase to start experiencing the benefits of and insights from your purchase. Important to note - the code provided is a single use code and only valid for the edition you purchase. It does not provide access to past nor future editions of the title.
You will have unlimited access to your eBook on the device to which it was downloaded.
Discover the various learning features that our eBooks offer on the Bookshelf® Reader! For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information on the learning functions can be found on the Vitalsource page.
Quality is our top priority. That's why we collaborate with the leading eBook reader provider VitalSource. VitalSource has its own eBook reader Bookshelf®, which you can easily download. This reader is very user-friendly and offers more features than other standard readers. For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information can be found on the Vitalsource page.
Elsevier offers its eBooks in ePub format, as we believe this format is best suited to display our content ideally on as many devices as possible.
You can return your eBook within 13 days of purchase. eBooks that have been partially printed or flipped through more than 15% are excluded from returns.
Any questions ?
Top Picks from Our Community
E-Book
Edited by Kimberly Washington
Nov 2025
E-Book
Edited by Prashanthi N. Thota
Nov 2025
E-Book
Edited by Christopher Filippi
Nov 2025
E-Book
Edited by Davis C. Thomas
Nov 2025
E-Book
Edited by Corey B. Simon
Nov 2025
E-Book
Edited by Catherine N. Petchprapa
Nov 2025
E-Book
Edited by Galal Omami
Nov 2025
E-Book
Edited by Hanan Goldberg
Nov 2025
E-Book
Edited by Sarah M. Perman
Nov 2025
E-Book
Edited by Michael W. Neumeister
Nov 2025
E-Book
Edited by Michael J. Alaia
Nov 2025
E-Book
Edited by Evie G. Marcolini
Nov 2025
E-Book
Edited by Kris Pyles-Sweet
Nov 2025
E-Book
Edited by Vin Paleri and Sue S. Yom
Nov 2025
E-Book
Edited by Frederick M. Azar
Nov 2025
E-Book
Edited by Brendon M. Stiles
Nov 2025
E-Book
Edited by Robert S. Brown Jr
Nov 2025
E-Book
Edited by Helio Autran de Morais
Nov 2025
E-Book
Nicholas J. Talley
Nov 2025
E-Book
Edited by Jeffrey D. Wayne
Nov 2025
E-Book
Edited by Andrew W. Harris
Nov 2025
E-Book
Edited by Arman Rahmim
Nov 2025
E-Book
Edited by Tamiko R. Katsumoto
Nov 2025
E-Book
Edited by Zoher Ghogawala
Nov 2025
E-Book
Edited by Consuelo C. Cagande
Nov 2025
Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
What Is the Current Status of Hepatitis B Virus Viro-Immunology?
Novel Assays to Solve the Clinical and Scientific Challenges of Chronic Hepatitis B
Overview of New Targets for Hepatitis B Virus: Immune Modulators, Interferons, Bifunctional Peptides, Therapeutic Vaccines and Beyond
Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers
Targeting Hepatitis B Virus DNA Using Designer Gene Editors
Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus
State of the Art: Test all for Anti-Hepatitis D Virus and Reflex to Hepatitis D Virus RNA Polymerase Chain Reaction Quantification
Triple Threat: HDV, HBV, HIV Coinfection
What Is the Real Epidemiology of Hepatitis D Virus and Why so Many Mixed Messages?
What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options
Test All for Hepatitis B Virus: Link to Care and Treatment if Quantitative DNA Positive, Vaccinate if Susceptible





